COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease

Pharmacoepidemiol Drug Saf. 2003 Jan-Feb;12(1):67-70. doi: 10.1002/pds.798.
No abstract available

Publication types

  • Review

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / epidemiology
  • Celecoxib
  • Clinical Trials as Topic
  • Cyclooxygenase 2
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors / adverse effects*
  • Cyclooxygenase Inhibitors / pharmacology
  • Dose-Response Relationship, Drug
  • Humans
  • Isoenzymes / antagonists & inhibitors*
  • Lactones / administration & dosage
  • Lactones / adverse effects
  • Lactones / pharmacology
  • Membrane Proteins
  • Naproxen / adverse effects
  • Naproxen / pharmacology
  • Prostaglandin-Endoperoxide Synthases
  • Pyrazoles
  • Sulfonamides / administration & dosage
  • Sulfonamides / adverse effects
  • Sulfonamides / pharmacology
  • Sulfones

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Cyclooxygenase 2 Inhibitors
  • Cyclooxygenase Inhibitors
  • Isoenzymes
  • Lactones
  • Membrane Proteins
  • Pyrazoles
  • Sulfonamides
  • Sulfones
  • rofecoxib
  • Naproxen
  • Cyclooxygenase 2
  • PTGS2 protein, human
  • Prostaglandin-Endoperoxide Synthases
  • Celecoxib